$GERN (NP)
Q2 report points to incremental turnaround
Rytelo demand +5% over Q1, revenue +11% and ordering accounts +8%
Operational runway for the foreseeable future
MF interim & final analysis = call option (8,000 2nd line patients in the US, no drug has hit on OS before)